On Our Radar
It’s not all about oncology (Part 3 - Hemophilia).
Following on BioMarin’s setbacks with a hemophilia gene therapy earlier this year, Novo invests in a spin out with experienced, home grown drug hunters and a bispecific antibody platform that produced spectacular results in Multiple Myeloma through Darzalex.